Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Birrer

Showing results (41-50 of 222) with videos related to

Pageof 23
Sort By:
Cancer Research|May 14, 2009
NORE1A tumor suppressor candidate modulates p21CIP1 via p53Diego F Calvisi, Howard Donninger, Michele D Vos, et al.
Molecular Cancer Research : MCR|May 14, 2009
A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancerBo Wang, Levon M Khachigian, Luke Esau, et al.
Gynecologic Oncology|March 12, 2008
Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasmsBehrang Litkouhi, Babak Litkouhi, Evelyn Fleming, et al.
Gynecologic Oncology|February 12, 2011
Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group studyJohn Farley, Leia M Smith, Kathleen M Darcy, et al.
The Journal of Biological Chemistry|March 2, 2005
Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cellsMotoo Katabami, Howard Donninger, Fumihiro Hommura, et al.
Gynecologic Oncology|August 11, 2018
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancerKathleen N Moore, David M O'Malley, Ignace Vergote, et al.
Human Pathology|August 7, 2004
Current challenges and opportunities for research on borderline ovarian tumorsMark E Sherman, Jules Berman, Michael J Birrer, et al.
Molecular Cancer Research : MCR|June 12, 2004
HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cellsFumihiro Hommura, Motoo Katabami, Virna D Leaner, et al.
Cancer Research|March 22, 2003
Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group studyJohn Farley, Leia M Smith, Kathleen M Darcy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studiesKristin K Zorn, Amir A Jazaeri, Christopher S Awtrey, et al.
Pageof 23

Showing results (41-50 of 222) with videos related to

Sort By:
Pageof 23
Cancer Research|May 14, 2009
NORE1A tumor suppressor candidate modulates p21CIP1 via p53Diego F Calvisi, Howard Donninger, Michele D Vos, et al.
Molecular Cancer Research : MCR|May 14, 2009
A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancerBo Wang, Levon M Khachigian, Luke Esau, et al.
Gynecologic Oncology|March 12, 2008
Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasmsBehrang Litkouhi, Babak Litkouhi, Evelyn Fleming, et al.
Gynecologic Oncology|February 12, 2011
Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group studyJohn Farley, Leia M Smith, Kathleen M Darcy, et al.
The Journal of Biological Chemistry|March 2, 2005
Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cellsMotoo Katabami, Howard Donninger, Fumihiro Hommura, et al.
Gynecologic Oncology|August 11, 2018
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancerKathleen N Moore, David M O'Malley, Ignace Vergote, et al.
Human Pathology|August 7, 2004
Current challenges and opportunities for research on borderline ovarian tumorsMark E Sherman, Jules Berman, Michael J Birrer, et al.
Molecular Cancer Research : MCR|June 12, 2004
HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cellsFumihiro Hommura, Motoo Katabami, Virna D Leaner, et al.
Cancer Research|March 22, 2003
Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group studyJohn Farley, Leia M Smith, Kathleen M Darcy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studiesKristin K Zorn, Amir A Jazaeri, Christopher S Awtrey, et al.
Pageof 23